The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2015
Filed:
Jun. 21, 2012
Ivanka Toudjarska, Cambridge, MA (US);
John M. Maraganore, Cambridge, MA (US);
Brian Bettencourt, Groton, MA (US);
Stuart Milstein, Cambridge, MA (US);
Martin A. Maier, Belmont, MA (US);
Klaus Charisse, Cambridge, MA (US);
Kallanthottathil Rajeev, Wayland, MA (US);
Satyanarayana Kuchimanchi, Weston, MA (US);
Ivanka Toudjarska, Cambridge, MA (US);
John M. Maraganore, Cambridge, MA (US);
Brian Bettencourt, Groton, MA (US);
Stuart Milstein, Cambridge, MA (US);
Martin A. Maier, Belmont, MA (US);
Klaus Charisse, Cambridge, MA (US);
Kallanthottathil Rajeev, Wayland, MA (US);
Satyanarayana Kuchimanchi, Weston, MA (US);
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
The invention relates to double-stranded ribonucleic acid (dsRNA) targeting a PROC gene, and methods of using the dsRNA to inhibit expression of PROC. At least one nucleotide of the dsRNA can be a modified nucleotide, e.g., a 2-0-methyl modified nucleotide, a nucleotide comprising a 5'-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Other examples of modified nucleotides include a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxymodified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. A dsRNA of the invention can include one or more of any of these modified nucleotides.